From Australia to China for Medical Care: Medicare Waits, PHI Blind Spots, Insurance Pathways, and a Decision Framework

Reading time: 18 minutes

In 2024, under Australia’s Medicare-covered public system, the national median wait for elective surgery was 49 days — but that’s only the “after you’re on the list” number. The wait from your GP’s referral to your first specialist appointment, then onto the surgical waiting list, is “invisible” wait time that’s routinely excluded from official statistics. The Australian Institute of Health and Welfare (AIHW) 2024 report shows the real cadence: median public wait of 175 days for total hip replacement, 271 days for total knee replacement [1]. In some states (Tasmania, Northern Territory), 15%–20% of patients sit in the “long tail” — waiting more than 365 days.

Private healthcare runs in parallel — and roughly 45% of Australian residents hold Private Health Insurance (PHI) underwritten by Bupa, Medibank, HCF, NIB, and others [21]. But the “blind spots” in this system are deeper than in the UK or US: a 12-month waiting period applies to pre-existing conditions and most major procedures (joint replacement, cardiac surgery, cataract), the Lifetime Health Cover (LHC) loading adds 2% per year for those who start after age 31, and Gap payments regularly leave even “fully insured” patients facing thousands of dollars in physician charges above the schedule fee.

This is why a growing number of Australian residents are asking: is there another route? And China is increasingly on that shortlist.

1. Where Australia’s healthcare system actually bottlenecks

Medicare is built on the principle “allocate by medical need, not by ability to pay” — same as Canada and the UK. But when demand outstrips supply, the allocation mechanism is queuing. AIHW 2024 data shows the real timeline [1][2]:

Procedure	Public median wait	90th percentile wait
Total hip replacement	175 days	393 days
Total knee replacement	271 days	514 days
Cataract surgery	87 days	277 days
Septoplasty	217 days	519 days
Tonsillectomy	184 days	397 days
Cardiac valve replacement	24 days	113 days
Coronary artery bypass	13 days	60 days
Cholecystectomy	51 days	197 days
MRI (non-urgent)	4–10 weeks	—
Specialist consult (oncology, urgent)	2–6 weeks	—
Specialist consult (orthopaedic)	8–26 weeks	—

What Medicare actually covers (and doesn’t) [3][4]:

Covered: GP visits (most bulk-billed at no cost), public hospital admissions and surgery, A&E, 85% of the MBS schedule fee for specialist consults, PBS-subsidised medications (general script $31.60, concession $7.70).
Not covered or partially covered: dental (apart from limited CDBS for some children), refractive surgery, most private specialist fees above MBS (the “Gap”), private hospital admission, more than 10 outpatient psychology sessions per year.
Medicare’s hard rule: you cannot pay out-of-pocket to jump the queue in a public hospital. You can step out of Medicare entirely into the private system, but that’s a parallel, market-priced track.

What Australian private healthcare actually looks like — more complex than in the UK or US:

Major private hospital groups: Ramsay Health Care [16], Healthscope (now under HMC Capital) [17], St Vincent’s Private [18], Epworth, Cabrini Melbourne.
The “Gap” trap: Medicare pays 75% of the MBS fee for inpatient specialist services; private insurance picks up the rest if your specialist is in a “Known Gap” or “No Gap” arrangement with your insurer. If they aren’t, the residual (often AUD $2,000–$8,000) is yours.
12-month waiting period: the biggest structural difference vs UK Bupa or NHS — major categories (joints, cardiac, cataract, obstetrics, assisted reproduction) cannot be claimed until 12 months have elapsed. “I just bought insurance for an upcoming surgery” doesn’t work.
Pre-existing condition rule: conditions, symptoms, or diagnoses present in the 6 months before joining attract a 12-month waiting period.
The “public in private” trap: even with PHI, if your operation happens in a public hospital, you stay in the public queue — PHI value only realises when you actively choose a private hospital and a private specialist.

2. Situations where “look at China” is a reasonable decision

Not every situation suits cross-border care. Below are the situations where, in our experience, Australian residents have a real case for considering China.

Situations that suit a China pathway

🟢 Wait-time-sensitive

Hip and knee replacement, spine decompression, cataract — public waits of 175–271 days, private with potentially thousands of dollars in Gap, procedures are mature, and you can fly home shortly after.
IVF evaluation — Australian PHI coverage of IVF is heavily restricted; out-of-pocket per cycle runs AUD $5,000–$10,000.
Elective surgery during the 12-month waiting period when you can’t wait that long — an Australia-specific scenario.

🟢 Diagnostic-acceleration cases

PET-CT for cancer staging or recurrence monitoring — bookable in 3–7 days in China; Medicare-restricted to specific indications in Australia, with private self-pay running AUD $1,200–$2,500.
High-field MRI, endoscopy — completed as a 3–5 day package in China.
Pathology slide re-reading — remote, no travel needed.

🟢 Second opinion and plan confirmation

An Australian diagnosis and treatment plan exists, and you want to pressure-test it.
Oncology, haematology, complex surgical decisions warranting MDT review.
Australian specialists generally welcome second opinions; an international second opinion (including from China) is defensible.

🟢 Advanced therapies that already point to China

CAR-T cell therapy — six NMPA-approved products in China at roughly 1/4 to 1/3 of Australia’s self-pay route (AUD $300K+; PBS coverage list is narrow) [12].
Proton and heavy-ion therapy — Australia has no operating heavy-ion centre; the first national proton centre (planned at SAHMRI, Adelaide) has been pushed back. China’s Shanghai Proton and Heavy Ion Center (SPHIC, public) and the Heyou Proton & Heavy Ion Center inside Heyou Pinnacle Medical Center (private, Foshan-Shunde) are among the very few centres on the Chinese mainland equipped with both proton and heavy-ion capability [13].
Certain biologics — broader access, lower pricing.

🟢 Premium executive physicals and early-cancer screening

Comprehensive packages completed in 3–5 days.
Imaging quality on par with top Australian private centres.
English-speaking International Medical Departments — no language barrier for Australian residents.

Situations that don’t suit China

🔴 Emergencies and critical illness — heart attack, stroke, major trauma, uncontrolled infection, severe bleeding. Handle locally. Crossing borders is itself the medical risk.

🔴 Unstable patients who can’t fly long-haul — fit-to-fly must be assessed by your existing treating physician (GP or specialist), not by us.

🔴 Expecting “a miracle cure” — if Australian oncology has called your case untreatable, “China must have something” is usually disappointment in waiting.

🔴 Price as the sole driver — Thailand or India may be cheaper for some procedures. China’s edge is the combination of clinical depth, price, and speed. Lowest price is not the headline.

3. Two systems in China — and a bridge that runs only one way

This is the part Australian patients most often misunderstand. We need to be explicit, because misunderstanding it costs you money.

Chinese hospitals fall into two distinct systems:

Public Tier-3A hospitals

Tier-3A (三级甲等) is the top rank in China’s hospital classification — equivalent to an Australian “major referral teaching hospital” (e.g., Royal Melbourne, Royal Prince Alfred Sydney).
Examples: Peking Union Medical College Hospital (Beijing), Beijing Tiantan Hospital, Shanghai Ruijin Hospital, Fudan-Zhongshan, Sun Yat-sen Memorial in Guangzhou, and many others.
Strengths: concentration of senior specialists, very high surgical volumes, can handle the most complex cases, costs are 30–50% of private international.
Weaknesses: limited English in general wards (you’ll need interpretation and accompaniment), queue logic built around domestic patient flow, inpatient wards utilitarian rather than hotel-grade.
The International Medical Department (IMD) is the dedicated bilingual channel inside top Tier-3A hospitals — Peking Union, West China, Ruijin, Huashan, Zhongshan and others all run IMDs designed for international patients.

Private international hospitals — more complex than you’d think from abroad

Examples: United Family Healthcare (Beijing/Shanghai/Guangzhou), Shanghai Jiahui International Hospital, Heyou Pinnacle Medical Center (Foshan-Shunde, founded by the founder of Midea Group with combined system investment of over RMB 10 billion), Concord Medical’s Guangzhou Concord Cancer Center (proton therapy operational from late 2024), and others.
Strengths go beyond service: fluent English, comprehensive insurance direct billing, hotel-style rooms, on-time appointments, transparent international workflow. But a small number of leading private hospitals also run equipment that matches or surpasses most public hospitals — Heyou Pinnacle’s affiliated Heyou Proton & Heavy Ion Center is led by Professor Lu Jiade, who established the clinical technology system at Shanghai SPHIC [13], making it one of the few proton-and-heavy-ion-capable centres on the Chinese mainland. Guangzhou Concord Cancer Center became South China’s first operating private proton therapy centre in late 2024.
Physician composition isn’t simple either: the overwhelming majority of China’s top specialists remain in the public Tier-3A system, but in recent years a smaller cohort of senior physicians have moved part-time or full-time into private hospitals, drawn by compensation, research autonomy, and lower administrative load. Heyou Pinnacle is the clearest case in point — beyond Lu Jiade, the group has attracted Li Baomin (national pioneer in neurointervention, 20,000+ stent placement and embolisation cases), Su Fengxi (Honorary President of Sun Yat-sen Memorial Hospital’s Breast Tumor Hospital, over 10,000 breast cancer surgeries, national leader in breast-conserving surgery), and other senior specialists. The blanket assumption “private equals weaker doctors” is too simple. What matters is who the lead surgeon is, what their actual surgical volume in that procedure is over the last 12 months, and the team behind them.
The real complexity: Chinese private hospitals are a hybrid system where the bulk of authority still sits in public Tier-3A, but local capability is iterating quickly in pockets. Which private hospital can perform which procedure at what level, who can take over post-op care, whether your insurance is in-network — these are case-by-case, hospital-by-hospital, surgeon-by-surgeon decisions. That’s the work MedCareInChina actually does.
Shared weakness: the most complex, specialty-defining procedures (top-tier oncology, complex cardiac, complex neuro, transplant) — public Tier-3A remains the primary route. Private coverage is expanding rapidly but unevenly.

⚠️ The one-way bridge — the rule you can’t afford to get wrong

Australian patients often assume they can “do diagnostics at private and surgery at public.” That path does not work in China.

The actual rule is asymmetric:

✅ Public → Private works. A diagnosis, imaging report, or prescription issued by a public Tier-3A hospital is recognised by private international hospitals. Private hospitals will continue prescribing, do follow-up, and conduct monitoring on the basis of the public hospital’s work.
❌ Private → Public does not. A private hospital’s consultation, imaging interpretation, or treatment plan is generally not accepted by a public Tier-3A as the basis for surgery or admission. If you want public treatment, the public hospital will require its own physicians to evaluate from scratch — frequently including repeat imaging and pathology review.

The reason: public Tier-3A is the higher-ranked tier in the Chinese medical hierarchy, and the downstream (private) accepts the upstream (public), but not vice versa.

What this means for your decision:

Complex cases (specialty-defining: top oncology, complex cardiac, complex neuro, transplant): stay in the public Tier-3A system end-to-end — from initial evaluation through surgery through follow-up. Same team, same chart, most accurate post-op judgment. If you bridge to private for follow-up of a complex case, any concerning finding will route you back to public anyway.
Routine cases (outpatient, imaging, executive physical, IVF, general specialty, dermatology, ophthalmology): stay in private international end-to-end. No reason to involve public.
The Public → Private follow-up bridge: appropriate for stable patients who’ve completed public treatment and need routine medication management or monitoring, especially those for whom English and service experience matter. Not appropriate for complex post-operative tracking.
❌ What not to do: assume you can run diagnostics at private and “save money by getting the surgery at public.” The result is paying for the workup twice.

4. Real cost comparison (AUD/USD, all at 1 USD = 6.5 RMB)

The table below combines AIHW public data, Australian private hospital price lists, and published price ranges from Chinese public and private international hospitals. All figures are ranges, not commitments. The final invoice depends on actual treatment, length of stay, complications, and insurance review.

Procedure	Australia Public (Medicare)	Australia Private Self-Pay	China Public IMD + Accompaniment	China Private International
Hip replacement	Wait 175 days, Medicare covers	AUD $25,000–$32,000	USD $8,000–$12,000	USD $15,000–$22,000
Knee replacement	Wait 271 days	AUD $25,000–$32,000	USD $8,000–$12,000	USD $15,000–$22,000
Spine fusion (single level)	Wait 6+ months	AUD $40,000–$55,000	USD $12,000–$18,000	USD $25,000–$35,000
Cataract (standard IOL, one eye)	Wait 87 days	AUD $3,500–$5,500	USD $800–$1,500	USD $2,500–$4,000
Cataract (premium multifocal IOL)	Not covered	AUD $6,000–$9,000	USD $2,000–$3,500	USD $4,500–$7,000
PET-CT	Partly covered (specific cancers)	AUD $1,200–$2,500	USD $1,500–$2,500	USD $2,500–$3,500
MRI	Wait 4–10 weeks	AUD $400–$900	USD $200–$500	USD $500–$900
Comprehensive checkup (incl. PET-CT)	Not covered	AUD $4,000–$9,000	USD $2,500–$4,500	USD $5,500–$9,500
Upper + lower endoscopy (with anaesthesia)	Wait 6–12 weeks	AUD $2,500–$4,500	USD $700–$1,500	USD $2,000–$3,500
IVF, single cycle	Medicare partial rebate	AUD $9,000–$13,000	USD $5,000–$8,000	USD $10,000–$16,000
CAR-T cell therapy	PBS list very narrow	AUD $500K+ (self-pay)	USD $160K–$220K (all-inclusive)	Not performed at private
Proton / heavy-ion therapy	No operating centre in Australia	Overseas private AUD $150K–$300K	USD $30K–$50K (SPHIC, public; proton + heavy-ion)	Heyou Pinnacle (proton + heavy-ion); Guangzhou Concord (proton); case-by-case

Notes on what the table doesn’t show:

Australian private specialists are largely public specialists moonlighting — clinical skill is the same as public; you’re paying to skip the queue and for service experience, not for a different doctor.
Medicare’s “free” coverage has a cost denominated in time. A patient waiting 271 days for a knee replacement and living on painkillers for nine months pays a real cost that isn’t money.
Australian private and Chinese private international prices are already close on some procedures. China private international is 30–50% cheaper than Australian private — but the bigger gap is wait time: 1–2 weeks in China vs 6–12 weeks at Australian private (limited by specialist OT slots).

5. Do Australian insurance plans actually work in China?

The honest answer: it depends on which plan you hold and whether your insurer has a direct-billing contract with your target hospital.

International medical insurance networks in China (2025 status)

The following are available to Australian residents and have substantial direct-billing networks in China [14]:

Bupa Global [6] — not the same as Bupa Australia. Expanded in 2025 to 3,600 designated hospitals across 300 cities, covering both public IMDs and private internationals. Bupa Australia domestic policies do not cover planned overseas treatment.
Cigna Global [5] — global network of 1.65M facilities; Shanghai operations centre; China direct billing covers both public and private.
AXA Global Healthcare [9] — AXA’s international product (distinct from AXA’s Australian operations). Via Prosper Health partnership, covers approximately 1,350 Tier-3A public hospitals (including PUMCH, Sun Yat-sen, Huashan) plus major private internationals.
Allianz Worldwide Care [7] — 280+ public IMD and private international hospitals in China. In Australia commonly held via expat schemes or international employer plans.
MSH International [8] — 500+ hospitals across 20+ cities, covering both public and private.
April International [10] — French-origin, available in Australia via brokers.

Plans that generally won’t work for planned care in China (Australian domestic PHI)

Bupa Australia (Gold/Silver/Bronze/Basic) — domestic PHI, does not cover planned overseas surgery.
Medibank Private — same.
HCF, NIB, HBF — Australian domestic PHI, do not cover planned overseas surgery.
Travel insurance — covers sudden illness and accidents only, not planned treatment.
Medicare overseas coverage — none. Australia maintains Reciprocal Health Care Agreements (RHCA) with several countries, but China is not one of them [11].

Direct billing vs reimbursement

Direct billing: the insurer pays the hospital directly; you cover only your deductible and copay. The widely repeated claim that “only private international hospitals support direct billing” is out of date — leading public Tier-3A IMDs now run extensive direct-billing networks. Concrete examples [14]:

Public IMD	Direct-billing insurers
Shanghai Huashan IMC	30+ direct billing contracts, ~100 actual partnerships; insurance business accounts for over 50% of revenue
Shanghai Ruijin IMD	20+ direct-billing insurers (system in place since 1998)
Peking Union (PUMCH) IMS	Maintains a full “Cooperative Commercial Insurance Roster” including major international insurers
Sun Yat-sen 1st Affiliated Hospital Nansha IMC	15 commercial insurers (opened 2023)

Private international hospital	Direct-billing insurers
Shanghai Jiahui International Hospital	~60 global insurers (broadest in East China)
Shanghai ParkwayHealth / SIMC	50+ direct billing; SIMC 60+ global partners
United Family Healthcare (Beijing/Shanghai/Guangzhou/Shenzhen/Boao)	22 international insurers
Heyou Pinnacle Medical Center (Foshan-Shunde)	Supports international commercial insurance direct billing; designated institution under the GBA “HK/Macao Drug & Device Access” policy

The decision criterion isn’t public vs private — it’s whether your specific insurer has an active direct-billing contract with the specific hospital you’re targeting. That has to be confirmed in writing before you travel.

Reimbursement (when direct billing isn’t available): you pay out of pocket, then claim back home. Almost all international policies accept this, but you’ll need:

English-language medical records, itemised bills, and the Chinese tax invoice (Fapiao).
Pre-authorisation filed with your insurer in advance (typically 24–48 hours processing).
Treatment falling within your policy scope.
A 4–12 week processing window.

What we can do, and what we don’t

⚠️ MedCareInChina is not an insurance company. We do not negotiate with your insurer on your behalf, and we do not advance insurance funds.

What we can do:

Help you confirm with your insurer whether your policy covers your planned treatment and whether your target hospital is in-network.
Help you prepare the pre-authorisation package your insurer requires (treatment plan, cost estimate, specialist letter).
Coordinate direct-billing communication and GOP (Guarantee of Payment) application between the Chinese hospital (public IMD or private international) and your insurer.
After discharge, organise your English-language medical records, bills, and payment receipts for your reimbursement claim back home.

What we don’t do:

Make insurance decisions for you.
Promise your insurer will approve.
Hold or pass through insurance funds (all medical fees go directly from you to the hospital).

6. The five steps of going from Australia to China for care

Total elapsed time from your first email to your return flight is roughly 6–12 weeks (not counting treatment itself).

Step 1 · Free Pathway Scan (1–2 business days)

Send us a short email. Tell us:

Your current condition or diagnostic direction
Your Australian state/city and a rough travel window
Whether you carry international medical insurance
A description of records you have on hand (no need to send files at this stage; description is enough)

We reply within 1–2 business days with:

Whether your situation is worth continuing to prepare for China
A recommended next step: remote consultation, direct travel, or stay in Australia
A short list of additional records to gather

This step is free, with no commitment. If we judge your situation isn’t right for China, we’ll tell you directly. We don’t push referrals.

Step 2 · Remote Expert / MDT Consultation (5–10 business days, paid)

If Step 1 confirms it’s worth continuing, the next step is remote consultation:

Single Expert: USD $800 flat — includes records organisation, Chinese case brief, specialist matching, video consultation, and a bilingual PDF report.
MDT (Multidisciplinary Team): USD $1,000 per specialist (a typical MDT = 3 specialists = USD $3,000) — suited for complex oncology, cross-specialty decisions.
Your records get translated and organised into a Chinese-language case brief.
We match a suitable Chinese specialist (public Tier-3A or private international, based on your case).
A video consultation is scheduled (you may attend or not).
A bilingual English-Chinese consultation report is delivered within 5–10 business days.

The deliverable is a formal medical opinion: the Chinese specialist’s view on your case, whether travel to China is recommended, candidate hospitals/cities/physicians, expected duration and cost range, and a next-step checklist.

You can take this report back to your Australian GP or specialist for discussion. You can also stop here and not proceed further — our service can end at this step.

Step 3 · S2 Medical Visa (2–4 weeks)

For Australian passport holders coming to China for medical reasons:

S2 visa [15][19]: medical treatment ≤6 months. The typical patient visa. Requires a Chinese-hospital-issued invitation letter or acceptance letter.
S1 visa [15][19]: medical treatment >6 months (long oncology protocols, etc.), allows accompanying family. Requires a long-term treatment confirmation from the hospital.
L visa (tourist): technically possible for a short single consultation, but not recommended — many hospital international departments don’t accept an L visa as a basis for sustained treatment.

⚠️ MedCareInChina does not process visas. We can coordinate the hospital to issue the invitation letter, but the visa application itself must be filed at the Chinese Embassy in Canberra or the Chinese Consulates in Sydney, Melbourne, Perth, Brisbane or Adelaide, via the CVASC (Chinese Visa Application Service Centre) [20].

The invitation letter typically takes 5–10 business days to obtain. Standard CVASC visa processing is 4–7 business days. Expedited service is available.

Step 4 · In-China Accompanied Care (during treatment)

Once you’re in China, we provide in-China accompanied care:

Airport pickup to hotel and hospital.
Appointment coordination: confirming your exams, surgery, and admission schedule.
Medical interpretation and accompaniment: bilingual support for exams, consultations, and pre/post-op communication.
Payment coordination: walking with you to the hospital cashier (the hospital Fapiao is issued directly to you).
Insurance documentation support: organising GOP, pre-authorisation, and discharge files for your reimbursement claim.
Discharge documents: English-language discharge summary, medication list, follow-up plan, imaging files (DICOM disc or cloud).
Hand-off back home: assistance coordinating with your Australian GP or specialist.

Typical durations in China: hip/knee replacement 5–7 days inpatient + 1–2 weeks recovery observation = 2–3 weeks total; cataract 1 outpatient day + 1–2 days observation = 3–4 days; comprehensive checkup 3–5 days.

Fee structure:

Consultation fee (paid at Step 2): paid to MedCareInChina.
Accompanied care service fee: based on your itinerary length and complexity, stated in writing before you sign.
Hospital and physician fees: paid directly to the hospital. MedCareInChina does not handle medical funds.
Hotel, flights, transport: you arrange and pay directly. We don’t book these.

Step 5 · Remote follow-up after returning home

Back in Australia:

Your Chinese attending physician schedules remote follow-up at agreed time points (video).
We continue to coordinate communication between the Chinese hospital and your Australian GP or specialist.
If your insurer requires additional documentation, we continue providing English-language materials.
If you face a medical emergency, seek local Australian emergency care immediately — do not try to reach the Chinese hospital for emergency handling.

7. When you shouldn’t consider China (the honest filter)

You’re currently admitted in an Australian hospital and unstable — flying poses higher risk than any benefit.
You don’t yet have baseline diagnosis, imaging, or medication records — we have nothing to evaluate and can’t prepare a remote consultation.
You’re hoping “China must have something” for late-stage disease that Australian oncology has called untreatable — managing that expectation isn’t something we can do, and the result is usually disappointment.
Cost is your only driver — Thailand or India may be more cost-optimal for your specific case.
You can’t accommodate a 6–12 week process — that’s the realistic time budget. If you can’t, don’t start.
Your insurance excludes overseas care and self-pay is genuinely outside your budget — re-read Section 4. If even the low end of the range is unmanageable, don’t start.

8. Frequently asked, honestly answered

Q: Can I have my Australian GP or specialist be involved from the start?
Yes — we encourage it. Consultation reports are bilingual by default specifically so you can hand them to your Australian clinician. We don’t replace your treating team; the goal is to add a viewpoint.

Q: Can the consultation report be used to support Bupa Global / AXA reimbursement?
Depends on your policy. The Chinese-language case brief, Chinese specialist opinion, and English report can serve as second-opinion evidence. Australian domestic PHI (Bupa Australia, Medibank, HCF, NIB) generally doesn’t reimburse planned overseas care. International insurers (Bupa Global, Cigna Global, AXA Global Healthcare, etc.) vary — confirm with the insurer directly.

Q: If something goes wrong during surgery, who’s responsible?
The Chinese hospital. MedCareInChina is not a medical provider, does not make medical decisions, and is not responsible for medical outcomes. All clinical judgments, surgical plans, and prescribing decisions are made by the Chinese hospital and physician you select, and they bear responsibility for outcomes. This is set out in our Terms of Service and Medical Disclaimer [22].

Q: Can I request a specific hospital or physician?
You can express a preference; we don’t guarantee we can match it. Final matching depends on the physician’s schedule, their willingness to take international patients, and whether your case actually fits their subspecialty. If your preferred match isn’t appropriate, we’ll suggest an equivalent alternative.

Q: Do I need a family member with me in China?
Not always. Outpatient and minor procedures (cataract, imaging, checkups) work fine solo. Major surgery and inpatient stays are strongly recommended with a family member (the S2 visa supports a separate accompanying-family application). If a family member isn’t possible, our accompanied-care service covers most practical needs.

Q: How soon after surgery can I fly back to Australia?
Depends on the procedure. Cataract — fly day 2. Joint replacement — typically 2–3 weeks observation plus a pre-flight medical assessment. Spine surgery — 3–4 weeks. Major cancer surgery — 4–6 weeks. Fit-to-fly assessment is required and is issued by the treating physician — we don’t issue Fit-to-fly.

Q: What if I arrive in China and the treatment turns out not to fit?
This is exactly why we insist on a remote consultation before travel. If the consultation concludes that China isn’t right for your case, we’ll tell you and explicitly recommend against coming. In the rare situation where, on arrival, additional Chinese-side workup uncovers something that changes the plan, the Chinese hospital and you make the new decision jointly. We facilitate communication — we don’t make medical decisions for you.

Q: Should I choose public or private in China? How do I decide?
This isn’t your choice to make blind — it’s a match based on your case. Complex specialty-defining cases (oncology, complex cardiac, neuro, transplant) — public Tier-3A is essentially the only option. Routine outpatient, imaging, checkup, general specialty — private international can handle the whole thing. In the middle (mid-complexity surgery, needing English plus insurance direct billing plus a degree of specialty depth) — that’s the genuine gray zone that requires case-by-case, physician-by-physician evaluation. That’s the work we do: matching your specific case to a city, hospital, and physician, with a defensible reason — not pointing you at a generic category of hospital.

9. Next step — send us your case

📧 hello@medcareinchina.com

Subject: Pathway Scan from Australia

In the body, tell us:

Your current condition or diagnostic direction (one or two sentences)
Your Australian state/city and rough travel window
Whether you carry international medical insurance (insurer name is enough — no policy number needed)
The state of your medical records (records, imaging, medication list — describe; don’t send files yet)

We respond within 1–2 Australian business days with a free written assessment.

This step is always free. No payment, no commitment, no follow-up marketing emails. If after reading the reply you decide it’s not for you, that’s the end of it. If you want to continue, we discuss the next step then.

Sources

[1] AIHW · Elective Surgery 2023-24 — Australian elective surgery waiting times national data. https://www.aihw.gov.au/reports-data/myhospitals/sectors/elective-surgery

[2] AIHW · Hospital Activity — Public hospital activity statistics. https://www.aihw.gov.au/reports/hospitals/hospital-activity

[3] Services Australia · Medicare — Official Medicare coverage scope. https://www.servicesaustralia.gov.au/medicare

[4] Department of Health · MBS Online — Official Medicare Benefits Schedule. http://www.mbsonline.gov.au/

[5] Cigna Global · International Health Insurance — China direct billing network. https://www.cignaglobal.com/

[6] Bupa Global · Find a Provider — Bupa Global policyholder network and direct-billing arrangements in China (2025 expansion to 3,600 designated hospitals across 300 cities). https://www.bupaglobal.com/en/customers/find-a-provider

[7] Allianz Care · International Medical Insurance — China provider network (280+ public IMD and private international hospitals). https://www.allianzcare.com/

[8] MSH International — China direct billing network (500+ hospitals across 20+ cities). https://www.msh-intl.com/

[9] AXA Global Healthcare — AXA’s international product (distinct from AXA Australia). Via Prosper Health partnership covers approximately 1,350 Tier-3A hospitals. https://www.axaglobalhealthcare.com/

[10] April International — French-origin, available in Australia via brokers. https://www.april-international.com/

[11] Australian Government · Reciprocal Health Care Agreements — China is not included. https://www.servicesaustralia.gov.au/reciprocal-health-care-agreements

[12] MedCareInChina · CAR-T Cell Therapy in China — China CAR-T pricing comparison and underlying data. https://medcareinchina.com/car-t-cell-therapy-in-china-six-approved-products-top-centers-pricing-and-comparison-with-western-centers/

[13] Shanghai Proton and Heavy Ion Center (SPHIC) + Heyou Pinnacle Medical Center (Foshan-Shunde) + Guangzhou Concord Cancer Center — Reference for proton and heavy-ion therapy options in China. Heyou Pinnacle’s Heyou Proton & Heavy Ion Center is directed by Professor Lu Jiade, who established the clinical technology system at SPHIC; Guangzhou Concord Cancer Center (Concord Medical Group) launched proton therapy operations in December 2024. https://medcareinchina.com/proton-and-heavy-ion-therapy-in-china-sphic-process-indications-and-comparison-with-us-japan-and-europe/

[14] MedCareInChina · International Medical Insurance and China Hospital Direct Billing — Reference article including the public IMD direct-billing roster (Huashan ~100 partnerships, Ruijin 20+, PUMCH cooperative insurance roster, Sun Yat-sen Nansha 15) and private hospital networks (Jiahui ~60, ParkwayHealth 50+, United Family 22, Heyou Pinnacle GBA designation). https://medcareinchina.com/international-medical-insurance-and-china-hospital-direct-billing-a-complete-guide-to-coverage-workflow-and-pitfalls/

[15] MedCareInChina · Complete Guide to China Medical Visa (S1/S2) — Reference article on S1 and S2 medical visa requirements. https://medcareinchina.com/complete-guide-to-china-medical-visa-s1-s2-the-first-step-for-international-patients/

[16] Ramsay Health Care Australia — Australia’s largest private hospital group; pricing reference. https://www.ramsayhealth.com.au/

[17] Healthscope Hospitals — Australia’s second-largest private hospital group. https://www.healthscope.com.au/

[18] St Vincent’s Private Hospital — Top-tier private hospital in Sydney/Melbourne. https://www.svph.org.au/

[19] Embassy of the People’s Republic of China in Australia · Visa Information — Official source for S1 and S2 medical visa rules for Australian applicants. http://au.china-embassy.gov.cn/eng/

[20] Chinese Visa Application Service Centre (CVASC) · Australia — Visa processing centres serving Australian residents (Sydney, Melbourne, Perth, Brisbane, Adelaide). https://www.visaforchina.cn/

[21] Private Healthcare Australia · PHI Statistics 2024 — Australian PHI coverage rates and Gap payment data. https://www.privatehealthcareaustralia.org.au/

[22] MedCareInChina · Service & Refund Policy / Medical Disclaimer / Privacy Policy — Full service boundary documentation. Service & Refund Policy · Medical Disclaimer · Privacy Policy

Last updated 2026-05-29. All USD/AUD/RMB conversions calculated at 1 USD = 6.5 RMB; actual exchange rate at settlement applies. All medical decisions remain between you and your treating physician. MedCareInChina provides patient navigation services; it is not a medical provider, does not diagnose, does not prescribe, and does not guarantee treatment outcomes.

— MedCareInChina Editorial Team